Brain stimulation device for thinking problems in people with schizophrenia
Tests a brain stimulation device against a sham device in adults with schizophrenia.
Plain-language title generated from the registry record
Registry title: TIS for Improving Cognitive Impairment in Schizophrenia
Key facts
- Where
- Changsha, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT07647380, who can take part
Where in China
- Second Xiangya Hospital, Central South UniversityChangsha, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Central South University
- Trial code
- NCT07647380
- Record updated
- 17 July 2026
- Original description
This study aims to evaluate the efficacy, safety, and underlying neural mechanisms of TIS targeting the hippocampus in ameliorating cognitive impairment associated with schizophrenia (CIAS). Researchers will compare active TIS to a sham control to see if TIS works to treat CIAS. Participants will receive TIS twice a day for 2 weeks. Their clinical data, including the baseline clinical symptom scale score, cognitive function, E/I imbalance index recorded by EEG, and MRI data, will be collected at baseline, at the end of the 2-week intervention, and 4 weeks after the intervention.Read full original descriptionShow less
Efficacy and Safety of Time Interference Stimulation on Cognitive Impairment in Patients With Schizophrenia
This study aims to evaluate the efficacy, safety, and underlying neural mechanisms of TIS targeting the hippocampus in ameliorating cognitive impairment associated with schizophrenia (CIAS). Researchers will compare active TIS to a sham control to see if TIS works to treat CIAS. Participants will receive TIS twice a day for 2 weeks. Their clinical data, including the baseline clinical symptom scale score, cognitive function, E/I imbalance index recorded by EEG, and MRI data, will be collected at baseline, at the end of the 2-week intervention, and 4 weeks after the intervention.
Inclusion: Age 18-50 years old; meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5) diagnostic criteria; the diagnosis of schizophrenia is confirmed by the Structured Clinical Interview for DSM-5 (SCID-5); the disease duration does not exceed 8 years; 1-2 antipsychotic drugs are taken, and the treatment dose of antipsychotic drugs was stable for at least 1 week before enrollment. Mood stabilizers, antidepressants, and excessive benzodiazepines (lorazepam when 2 doses exceeded 2 mg/d) are not allowed; The type of antipsychotic drugs remains unchanged during treatment, and the dose is adjusted by no more than 25%; Impaired functioning in daily activities; The Global Deficit Score (GDS) for the MATRICS Consensus Cognitive Battery (MCCB) reaches 0.5 or above; Agree to participate in this study and provide written informed consent.
Exclusion: with clear drug-induced extrapyramidal reaction; have received other regimens of electrical or magnetic therapy in 1 month before enrollment; Presence of other psychiatric comorbidities, intellectual disability, obvious mood symptoms, or substance use disorders (other than caffeine and/or tobacco); A history of seizures, meningitis, or encephalitis; History of intracranial tumors or surgery; history of severe head trauma; with contraindications to transcranial electrical stimulation.